Clinical trials

Colorectal cancer
#AACR #Cancer research #Cardiff Oncology #Clinical trials #Colorectal cancer #KRAS

Promising data for onvansertib in combination with standard-of-care  

Findings from Cardiff Oncology’s Phase Ib portion of the Phase Ib/II study for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC) have been published in Clinical Cancer Research, a journal of the American Association for Cancer Research.  The publication underscores the safety… Read More

#Cancer Research #News

Patient using a mammography machine
#Breast cancer #Cancer research #Clinical trial design #Clinical trials #Oncology #Phase II trial #Phesi

Breast cancer most researched disease area for third year running

Breast cancer was the most studied disease in 2023 for the third consecutive year, followed by solid tumours, stroke, Covid-19 and prostate cancer. The analysis of 65,749 recruiting clinical trials was conducted by data analytics company Phesi, as part of an annual global analysis of clinical… Read More

#Cancer Research #News #Trending News

Brain physiology
#Clinical trials #European Medicines Agency #Neuroscience #Synendos Therapeutics

EMA approves endocannabinoid system modulator trial

Synendos Therapeutics, has received approval from the European Medicines Agency (EMA) to commence the Phase I first-in-human clinical trial of its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the endocannabinoid system (ECS) to restore healthy brain physiology.   The randomised, double-blind, placebo-controlled study will… Read More

#News #Regulatory

Pancreatic cancer
#AI #ASCO #Cancer research #Clinical trials #FDA #Neurology #Oncology #Orphan drugs #Pancreatic cancer #Rare disease

Phase IIa results for combination pancreatic cancer therapy  

BPGbio, an AI-powered biopharma that focuses on oncology, neurology, and rare diseases, has announced new data from a Phase IIa clinical trial of its lead candidate, BPM31510, in patients with advanced pancreatic cancers at the annual ASCO Gastrointestinal Cancers Symposium, being held 18-20 January 2024, in San Francisco. Read More

#Cancer Research #News

Cytokine release syndrome
#Cancer treatment #Clinical trials #Haematology #Immunotherapy #Institute of Cancer Research #Poolbeg Pharma

Treatment potential for immunotherapy-induced CRS

Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS).   POLB 001 demonstrated efficacy in reducing… Read More

#Cancer Research #News

Handshake jigsaw puzzle
#Cancer #Clinical trials #Drug development #Paediatrics

Advancing paediatric cancer research through partnerships 

Paediatric oncologist Gauri Sunkersett shares her unique background and research approach at AbbVie to help find answers for the youngest blood cancer patients.   When I was a second-year resident training as a paediatric oncologist at Nicklaus Children’s Hospital, I met a teenage boy diagnosed with Hodgkin’s Lymphoma. He was admitted… Read More

#Exclusive Content

#Cancer research #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Neuroscience #Oncology

DDW readers’ top drug discovery developments of 2023

DDW’s Diana Spencer takes a look at the breaking news stories that were most popular with DDW readers over the last year. Representing a dominant field of drug discovery, it isn’t surprising that breakthroughs in cancer research were popular with DDW readers in 2023, particularly strategies to overcome treatment resistance… Read More

#Exclusive Content

Digital biomarkers
#AI / data analytics / healthtech / informatics #Biomarkers #Biosecurity #Clinical trials #Digital biomarkers

Beyond blood tests: The evolution of digital biomarkers in clinical research

Digital biomarkers promise to transform preventive medicine and clinical trials, but also raise issues of security, regulation and potential disparities in access. Deepika Khedekar, Clinical Trial Lead at IQVIA, provides an overview of the pros and cons, and suggests a possible solution. The human body, a complex tapestry of over… Read More

#Exclusive Content #Opinion

Breast cancer research
#Antibody drug conjugate (ADC) #Breast cancer #Cancer research #Clinical trials #Oncology

The latest advances in breast cancer therapy

A number of companies presented breakthrough data for their investigational breast cancer drugs at the San Antonio Breast Cancer Symposium. Antibody drug conjugate MBRC-101 MBrace Therapeutics presented preclinical data demonstrating the potential of its novel antibody drug conjugate MBRC-101 for the treatment of solid tumours including… Read More

#Cancer Research #News #Trending News

Follicular lymphoma
#AbbVie #Bispecific Antibodies #Clinical trials #Follicular lymphoma #Genmab

New data for relapsed/refractory follicular lymphoma treatment 

Genmab and AbbVie have announced updated data presented at ASH from the companies’ ongoing Phase I/II EPCORE NHL-1 clinical trial investigating epcoritamab (DuoBody CD3xCD20).   Epcoritamab is a T-cell engaging bispecific antibody administered subcutaneously in 128 adult patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma… Read More

#News

Eye health ophthalmology
#Clinical trials #Diabetes #Exonate #Eye health #mRNA #Ophthalmology #Small molecules

Trial in diabetic macular oedema successfully completed  

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study.   During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity. Exonate… Read More

#News

Cancer research
#Clinical trials #Paediatrics #Pharming #Phase III trial #Rare disease

Trials investigate targeted APDS treatment in a paediatric setting

The first patient has been dosed in a Phase III study evaluating a paediatric granulated formulation of leniolisib in children with activated phosphoinositide 3-kinase delta syndrome (APDS). Pharming’s investigational drug leniolisib is an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. At sites in the… Read More

#News

AI clinical trials concept
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Clinical trial design #Clinical trials

Decoding diseases: The AI renaissance in clinical trials

Listen to this article on the DDW Podcast: Deepika Khedekar, Associate Centralized Clinical Lead at IQVIA, explains how artificial intelligence could make clinical trials more accurate, accessible and standardised. Over 19 million1 hearts succumb to cardiovascular disease yearly, while around 10 million2 lives are claimed by cancer every year. To put… Read More

#Exclusive Content

#Cancer #Cancer drug targets #Clinical trials #Drug discovery #Psychedelics

New DDW Highlights podcast: 6 November 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news highlights this week feature a variety of exciting clinical trial… Read More

#News

#Cancer #Cancer drug targets #Clinical trials #Drug discovery #Psychedelics

This week in drug discovery (30 Oct-3 Nov)  

News round-up for 30 October – 3 November by DDW Editor Reece Armstrong My news highlights this week feature a variety of exciting clinical trial results and launches that are examining therapies for much-needed disease areas, new drug approvals and even a space mission with a pharma twist. Read More

#News

ESMO 2023
#Cancer research #Clinical trials #ESMO #Oncology

Breaking clinical trial news from ESMO 2023

The European Society for Medical Oncology Meeting (ESMO) 2023 took place from 20-24 October in Madrid, Spain. Many drug discovery companies took the opportunity to share their latest cancer research findings. Axicabtagene ciloleucel, Kite Two indirect comparative analyses of CAR T-cell therapy axicabtagene ciloleucel vs. bispecific… Read More

#Cancer Research #News #Trending News